JTO Authority Review: Efficacy and Safety of Neoadjuvant Targeted Therapy for Resectable NSCLC
The standard treatment (SoC) for surgically resectable early-stage (I-IIIB) NSCLC patients is surgery combined with (new) adjuvant systemic therapy for patients with stage II to IIIB and certain stage IB patients, with chemotherapy and radiotherapy used in select cases (for stage III disease with mediastinal lymph node metastasis). Despite these treatments, metastatic recurrence is common … Read more